BIFLURANOL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)

Bifluranol, a fluorinated bibenzyl drug with antiandrogenic properties has been studied for its efficacy in the treatment of benign prostatic hyperplasia. Thirty five patients with bladder outflow obstruction received either Bifluranol 1.5 mg orally, t.d.s. or placebo in a double-blind trial. After twelve weeks there was improvement in symptoms of flow, urinary stream (p < 0.01) and frequency (p < 0.05) in the Bifluranol treated group. A significant reduction in residual urine volume was noted in the active treated group (p < 0.05) but mean and peak urine flow rates, voided volume and prostate volume did not reach statistical significance. It is concluded that Bifluranol has a measurably beneficial effect in urinary outflow obstruction due to BPH and further investigative studies with this drug are in progress.